Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
New study solves lung transplant rejection mystery

New study solves lung transplant rejection mystery

Blood biomarkers offer hope for early detection of interstitial lung disease

Blood biomarkers offer hope for early detection of interstitial lung disease

POT1 gene mutation linked to pulmonary fibrosis through telomere dysfunction

POT1 gene mutation linked to pulmonary fibrosis through telomere dysfunction

AI toolset reveals links between lung fibrosis and aging

AI toolset reveals links between lung fibrosis and aging

Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF)

Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF)

New drug discovery platform aims to deliver first-in-class therapies

New drug discovery platform aims to deliver first-in-class therapies

Study investigates aging-related mechanisms in idiopathic pulmonary fibrosis using AI approaches

Study investigates aging-related mechanisms in idiopathic pulmonary fibrosis using AI approaches

Double lung transplant patient completes 32-mile Manhattan walk

Double lung transplant patient completes 32-mile Manhattan walk

AI reshapes ARDS care by predicting risk, guiding ventilation, and personalizing treatment

AI reshapes ARDS care by predicting risk, guiding ventilation, and personalizing treatment

New 3D bio-printed model closely mimics the complexity of natural lung tissue

New 3D bio-printed model closely mimics the complexity of natural lung tissue

Blocking Epac1 protein slows lung fibrosis in preclinical models

Blocking Epac1 protein slows lung fibrosis in preclinical models

Targeting SRSF7 offers potential therapy for pulmonary fibrosis

Targeting SRSF7 offers potential therapy for pulmonary fibrosis

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

New cryogenic mass spectrometry approach reveals inner structure of lipid nanoparticles

New cryogenic mass spectrometry approach reveals inner structure of lipid nanoparticles

Tulane researchers identify a potential new way to treat idiopathic pulmonary fibrosis

Tulane researchers identify a potential new way to treat idiopathic pulmonary fibrosis

Blocking Piezo2 may offer a new therapeutic approach for pulmonary fibrotic diseases

Blocking Piezo2 may offer a new therapeutic approach for pulmonary fibrotic diseases

Insilico Medicine's AI-driven drug Rentosertib receives official generic name

Insilico Medicine's AI-driven drug Rentosertib receives official generic name

Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025

Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.